세포 및 유전자 치료 바이오 제조 시장 규모는 2022년 126억 달러, 2023년 139억 달러에서 예측 기간 동안 10.60%의 복합 연간 성장률(CAGR)로 성장을 지속하여 2032년에는 312억 달러 규모로 성장할 것으로 예측됩니다. 시장 성장을 가속하는 주요 요인은 세포 및 유전자 치료 연구에 대한 투자 증가입니다.
세포 및 유전자 치료 시장은 급속한 성장을 이루고 있으며, 제조 솔루션에 대한 수요 증가가 세포 및 유전자 치료 바이오 제조 시장을 견인하고 있습니다. 유망한 임상시험 결과나 신규 세포 및 유전자 치료 승인을 받아 상업화의 요건을 충족하기 위해 제조량을 늘릴 필요성이 높아지고 있습니다. 시장의 급격한 성장으로 효율적이고 확장 가능하며 비용 효율적인 바이오 제조 공정과 인프라 개발이 요구되고 있습니다. 세포 및 유전자 치료 제품 수요 증가에 대응하여, 바이오 제조 기업은 자동화, 일회용 시스템, 클로즈드 시스템,바이오리액터 등의 첨단 기술에 투자하고 있습니다.
지역별 전망
이 시장은 다양한 요인들로부터 북미가 지배적 입장에 위치하고 있습니다. 첫째, 북미에는 세포 및 유전자 치료 R&D에 적극적으로 관여하는 제약회사와 생명공학기업의 활발한 생태계가 있습니다. 둘째, 북미에는 확립된 규제 프레임워크과 지원 정책이 있어 시장 성장을 가속하고 있습니다.
유럽의 세포 및 유전자 치료 바이오 제조 시장은 2위 시장 점유율을 나타내며, 이는 유능한 인재에 기인하고 있습니다. 유럽이 2위 점유율을 획득한 배경에는 유능한 인재, 고급 인프라, 확립된 바이오 의약품 산업을 보유하고 있는 등 몇 가지 요인이 있습니다.
아시아태평양 시장은 2024년부터 2032년까지 가장 빠르게 성장할 것으로 예상됩니다. 이 지역의 바이오 의약품 산업은 특히 세포 및 유전자 치료 분야로의 R&D 증가에 의해 가속적인 성장을 이루고 있습니다.
본 보고서에서는 세계의 세포 및 유전자 치료 바이오 제조 시장을 조사했으며,, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이와 예측, 각종 구분, 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032
In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.
The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth as a result of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.
Market segment insights
Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.
Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.
Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.
The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.
Regional Perspectives
The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America because of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.
The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.
The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth as a result of the growing investment in research and development, particularly in the fields of cell and gene therapy.
Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.
2.2.3.LIMITATIONS
3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS